| Project/Area Number |
15K18933
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
AOMORI Tohru 慶應義塾大学, 薬学部(芝共立), 准教授 (40620802)
|
|---|
| Research Collaborator |
TSUCHIYA Ayumi
SAKAMOTO Mami
TAKEUCHI Arisa
ISHIOKA Eriko
KANEKO Yuko
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | アザチオプリン / 関節リウマチ / inosine triphosphatese / ITPA / inosine triphosphatase |
|---|
| Outline of Final Research Achievements |
The aim of this study was to evaluate the association between the genetic polymorphisms of azathioprine (AZA) -metabolizing enzymes and their influence on rheumatoid arthritis treatment.
As a result of comparison between patients with and without mutation in inosine triphosphatase (ITPA), one of the metabolic enzymes of AZA, the dosage of AZA was 0.851±0.302 mg/kg/day in the mutant group, while 1.24±0.463 mg/kg/day in the wild type group. On the other hand, there was no significant difference between the two groups in the change of DAS28 during 6 months, which is an index of the therapeutic effect. As a conclusion, patients with ITPA mutation had equivalent therapeutic effect with a lower dose compared with patients without the mutation.
|
